- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02882204
Tracking Outcomes in Psychosis (TOPSY)
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
OBJECTIVES: The objective of this study is to investigate the pathophysiology of Formal Thought Disorder and variable outcomes in the early stages of schizophrenia. In particular, investigators aim to test the hypothesis that 1. Anatomical abnormalities involving the grey matter of the Anterior Insula and Medial Prefrontal Cortex in first episode schizophrenia predicts FTD that persists by 6 months of illness 2. An excess of glutamine/glutamate, or reduction in glutathione, in Medial Prefrontal Cortex at index episode will be associated with persistent FTD 3.Aberrant connectivity between Anterior Insula and Medial Prefrontal Cortex will specifically predict the severity of persistent FTD irrespective of the stage of illness; the change in this connectivity will track the variable 3-year outcome among patients with first episode of psychosis.
METHODS: This study will employ a cross-sectional design recruiting n=126 participants from the Prevention & Early Intervention Program for Psychoses (PEPP). Four groups of participants will be assessed: patients at a later stage of schizophrenia (chronic illness group) (n=42), newly referred first episode group of PEPP patients (n=84), Clinical High Risk patients (n=60) and healthy Controls (n=45). Measurements: Patients will be diagnosed using the criteria for schizophrenia according to DSM-V(34). Demographic variables such as age, gender and parental socioeconomic status will be recorded to adjust for potential confounding effects. Patients will undergo baseline assessments to assess seven features of FTD (poverty of speech, weakening of goal, perseveration, looseness, peculiar word usage, peculiar sentence usage and peculiar logic) in line with the validated procedure for administering Thought Language Index [TLI](17). First episode patients will undergo four 7T MRI scanning sessions over the course of 2.5 years (baseline, 6 months, 18 months, 30 months)lasting for 60 minutes each, as described in our previous work (15). During this time, researchers will perform MR spectroscopy (MPFC voxel (31)), T1 weighted structural scan and eyes-closed, task-free, 6 minutes resting-state functional MRI. 6 months after the onset of first episode, the clinical assessment will be repeated using TLI. Patients with persistent FTD will be identified (from previous studies, 40% of patients are expected to have persistent FTD (9)) and separated from patients who have no FTD at 6-months time point. Patients with established illness will undergo only 2 scans: baseline and 1 year later.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studiecontact
- Naam: Lena Palaniyappan, MD, PhD
- Telefoonnummer: 519.685.8054
- E-mail: lena.palaniyappan.@lhsc.on.ca
Studie Locaties
-
-
Ontario
-
London, Ontario, Canada, N6A 5B7
- Werving
- Robarts Research
-
Contact:
- Lena Palaniyappan, MBBS, PhD
- Telefoonnummer: 519-685-8054
- E-mail: lena.palaniyappan@lhsc.on.ca
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Study population includes two groups of individuals:
- First Episode psychotic patients: This group will contain 84 new patients enrolled in the Prevention and early Intervention Program for Psychosis.
- Chronic Patients: This group will contain 42 patients who have been enrolled in the Prevention and Early Intervention Program for Psychosis for >3 years.
- Healthy Controls: This group will contain 42 healthy controls not being treated for a major mental illness defined using DSM-V criteria.
Beschrijving
Inclusion Criteria:
- 16-45 years old
- Outpatient of the Prevention and Early Intervention Program for Psychosis
Exclusion Criteria:
- Drug or alcohol dependence in past year
- History of head injury (with associated unconsciousness for any period)
- Mental retardation or suffering from medical conditions such as untreated hypertension, diabetes, hepatic/renal insufficiency, neurological illnesses
- Otherwise unable to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
|---|
|
First Episode Patients
First episode patients new to the PEPP program.
|
|
Chronic Patients
Existing patients who have been enrolled in the PEPP program for >3 years
|
|
Healthy Controls
Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
|
|
Cliniucal High Risk patients
Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Thought Language Index Score between baseline and 6 months
Tijdsspanne: 6 Months
|
Predicting the change in TLI score based on baseline anatomical abnormalities identified through MRI
|
6 Months
|
|
Time to remission of positive symptoms of psychosis
Tijdsspanne: 30 months
|
The time between baseline and remission of positive symptoms based on PANSS-8
|
30 months
|
|
Time to remission of negative symptoms of psychosis
Tijdsspanne: 30 months
|
The amount of time between baseline and remission of negative symptoms based on PANSS-8
|
30 months
|
|
Emergence of treatment resistance using operational criteria
Tijdsspanne: 30 months
|
30 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Thought Language Index score between baseline and longitudinal follow up-dates (12 months, 18 months, 24 months and 30 months)
Tijdsspanne: 1-2.5 years
|
Net change in TLI score as predicted by anatomical abnormalities associated with imaging at various imaging time points.
|
1-2.5 years
|
|
Change in overall symptoms over time
Tijdsspanne: 30 months
|
Tracking changes in scores on the PANSS-8 over the 30 months of follow up for first episode patients
|
30 months
|
|
Changes in myelin content
Tijdsspanne: 30 months (follow up period for first episode patients)
|
Longitudinal changes in myelin content as measured using quantitative t1 images
|
30 months (follow up period for first episode patients)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Harrow M, Marengo JT. Schizophrenic thought disorder at followup: its persistence and prognostic significance. Schizophr Bull. 1986;12(3):373-93. doi: 10.1093/schbul/12.3.373.
- Palaniyappan L, Mahmood J, Balain V, Mougin O, Gowland PA, Liddle PF. Structural correlates of formal thought disorder in schizophrenia: An ultra-high field multivariate morphometry study. Schizophr Res. 2015 Oct;168(1-2):305-12. doi: 10.1016/j.schres.2015.07.022. Epub 2015 Jul 29.
- Liddle PF, Ngan ET, Caissie SL, Anderson CM, Bates AT, Quested DJ, White R, Weg R. Thought and Language Index: an instrument for assessing thought and language in schizophrenia. Br J Psychiatry. 2002 Oct;181:326-30. doi: 10.1192/bjp.181.4.326.
- Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, Menon RS, Rajakumar N, Pavlosky WF, Densmore M, Schaefer B, Williamson PC. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011 Jun;198(6):448-56. doi: 10.1192/bjp.bp.110.079608.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) (2013).
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 10014067
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .